Breaking News Instant updates and real-time market news.

NFLX

Netflix

$161.70

0.58 (0.36%)

, BRO

Brown & Brown

$43.01

-0.29 (-0.67%)

17:50
07/17/17
07/17
17:50
07/17/17
17:50

On The Fly: After Hours Movers

UP AFTER EARNINGS: Netflix (NFLX), up 10.6%... Brown & Brown (BRO), up 4.6%. ALSO HIGHER: Rite Aid (RAD), up 7.4% after it said that adjustments from the Walgreens (WBA) deal to pro forma adjusted EBITDA will result in pro-forma adjusted EBITDA for the year ended March 4, 2017 of $742.97M. DOWN AFTER EARNINGS: Select Comfort (SCSS), down 4%... Floor & Decor (FND), down 1.2%. ALSO LOWER: CymaBay (CBAY), down 5.5% after it filed to sel 10M shares of common stock... Ethan Allen (ETH), down 4.6% after it reported lower-than-expected preliminary earnings for Q4... Viper Energy (VNOM), down 4.4% after it announced a public offering of 11M common units... Annaly Capital (NLY), down 3.1% after it filed to sell 60M shares of common stock... Ford (F), down marginally after Bloomberg reported that it approached electric vehicle company Lucid Motors, which is raising funds for expansion.

NFLX

Netflix

$161.70

0.58 (0.36%)

BRO

Brown & Brown

$43.01

-0.29 (-0.67%)

RAD

Rite Aid

$2.31

-0.02 (-0.86%)

WBA

Walgreens Boots Alliance

$79.18

0.27 (0.34%)

SCSS

Select Comfort

$31.81

1.05 (3.41%)

CBAY

CymaBay

$5.98

0.33 (5.84%)

ETH

Ethan Allen

$30.45

-0.15 (-0.49%)

VNOM

Viper Energy

$16.20

0.03 (0.19%)

NLY

Annaly Capital

$12.26

-0.07 (-0.57%)

F

Ford

$11.74

0.06 (0.51%)

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 19

    Jul

  • 26

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

NFLX Netflix
$161.70

0.58 (0.36%)

07/13/17
MSCO
07/13/17
NO CHANGE
Target $185
MSCO
Overweight
Morgan Stanley sees Netflix international markets ramping, ups target to $185
Morgan Stanley analyst Benjamin Swinburne said the firm's analysis of Netflix's content points to a positive correlation between the number of titles offered and the level of subscriber penetration in a given region. The analyst, who increased his 2018 international net subscriber additions forecast based on increased conviction in accelerating penetration in newer markets, raised his price target on Netflix to $185 from $175 and keeps an Overweight rating on the shares.
07/14/17
FBRC
07/14/17
NO CHANGE
Target $145
FBRC
Market Perform
Netflix search trend checks positive for Q2, says FBR Capital
FBR Capital analyst Barton Crockett says his pre-earnings channel checks of Google search volume for Netflix inflected positively, globally, in Q2. The analyst views the checks as a positive indicator ahead of Netflix's post-close earnings report on Monday. In the U.S., Netflix searches rose 2% year-over-year, reversing a 6% decline in Q1, Crockett tells investors in a research note. Search volumes also moved up in Latin America, the analyst points out. Crockett keeps a Market Perform rating on the shares with a $145 price target.
07/12/17
WEDB
07/12/17
NO CHANGE
Target $73
WEDB
Underperform
Wedbush sees Netflix topping Q2 subscriber guidance, keeps Underperform rating
Wedbush analyst Michael Pachter, who acknowledges in a note to investors that he has been "consistently wrong about this stock," said he expects Netflix to report significant upside to its Q2 streaming subscriber guidance and give Q3 subscriber growth guidance at or above the just-completed quarter's levels. Still, he is maintaining his Underperform rating and $73 price target on Netflix shares, as he expects its cash burn to continue for many years and sees "spotty execution" for its expensive Originals strategy.
07/12/17
UBSW
07/12/17
NO CHANGE
Target $175
UBSW
Buy
UBS survey suggests strong subscriber growth for Netflix
UBS analyst Doug Mitchelson said the UBS Evidence Lab download analysis and content tracking shows very strong momentum for Q2 subscriber growth for Netflix. As a result, the analyst believes expectations are reasonable heading into Q2 results and guidance. He is maintaining his estimates in line with consensus but sees upside to Street net additions for the year. Mitchelson reiterated his Buy rating and $175 price target on Netflix shares.
BRO Brown & Brown
$43.01

-0.29 (-0.67%)

12/16/16
JPMS
12/16/16
UPGRADE
Target $45
JPMS
Neutral
Brown & Brown upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Sarah DeWitt upgraded Brown & Brown to Neutral saying the company has the most upside of the names she covers from potential U.S. corporate tax reform. The analyst raised her price target for the shares to $45 from $35.
12/12/16
BMOC
12/12/16
UPGRADE
BMOC
Market Perform
Brown & Brown upgraded on tax outlook at BMO Capital
As noted earlier, BMO Capital upgraded Brown & Brown to Market Perform from Underperform . Analyst Charles Sebaski expects federal tax cuts to boost non-life insurers' results in 2018. Target $46.
12/12/16
BMOC
12/12/16
UPGRADE
BMOC
Market Perform
Brown & Brown upgraded to Market Perform from Underperform at BMO Capital
11/04/16
BMOC
11/04/16
DOWNGRADE
BMOC
Underperform
Brown & Brown downgraded on profit outlook at BMO Capital
As noted earlier, BMO Capital downgraded Brown & Brown to Underperform from Market Perform. Analyst Charles Sebaski expects the company's EPS growth to be constrained by "margin pressures and lack of capital management." Target to $37 from $39.
RAD Rite Aid
$2.31

-0.02 (-0.86%)

06/30/17
06/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with an Underperform at Evercore ISI. 2. Hill-Rom (HRC) initiated with a Buy at Needham and Neutral at Cantor. 3. Dermira (DERM) initiated with an Outperform at Evercore ISI. 4. Coach (COH) initiated with a Buy at Canaccord. 5. WWE (WWE) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/17
JEFF
06/29/17
NO CHANGE
Target $95
JEFF
Buy
Jefferies sees Walgreens topping new synergy target
Jefferies analyst Brian Tanquilut fully expects Walgreens Boots Alliance (WBA) to exceed its new synergy target from the purchase of Rite Aid (RAD) stores. He also expects the FTC to approve the new agreement as he thinks Walgreens wouldn't have entered into it if the agency wasn't fully aware and on-board with the revised transaction. The analyst views the recent pullback in Walgreens shares as overdone and keeps a Buy rating on the name with a $95 price target.
06/30/17
EVER
06/30/17
INITIATION
EVER
Underperform
Rite Aid reinstated with an Underperform at Evercore ISI
Evercore ISI analyst Ross Muken reinstated Rite Aid with an Underperform rating, versus In-Line previously, to reflect threats from online competition, structural challenges at the back-end of pharmacy given network positioning, and limited strategic options. The analyst sees downside near-term to $2.00-$2.50 per share.
06/30/17
COWN
06/30/17
NO CHANGE
Target $5
COWN
Outperform
Rite Aid better positioned following new agreement, says Cowen
Cowen analyst Charles Ryhee said he is positive on the new Rite Aid (RAD) agreement with Walgreens (WBA) as it better positions the company than had it remained stand-alone with no deal at all. Benefits include deleveraging, lower generic procurement costs, increased financial flexibility and "great" leverage toward PBM, which is growing faster than retail. Ryhee reiterated his Outperform rating and $4.70 price target on Rite Aid shares.
WBA Walgreens Boots Alliance
$79.18

0.27 (0.34%)

06/30/17
06/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cabot Oil & Gas (COG) upgraded to Buy from Neutral at BofA/Merrill with analyst Doug Leggate saying Cabot 's gross Marcellus takeaway capacity will increase to 3.7 bcf/d from 2bcf/d by end of 2018 and positioned to increase free cash flow to $2B from $872M per year for 25 years. 2. Becton Dickinson (BDX) upgraded to Strong Buy from Outperform at Raymond James with analyst Lawrence Keusch saying he believes it should be a core holding based an an above average outlook for 5%-6% organic growth and mid-teens earnings increases with further potential upside. 3. Walgreens Boots Alliance (WBA) upgraded to Buy from Hold at Needham. 4. ManTech (MANT) upgraded to Buy from Hold at Loop Capital with analyst Joseph Vafi saying he sees "company-specific and secular catalysts" driving improving fundamentals and upward revisions to consensus estimates. 5. D.R. Horton (DHI) upgraded to Outperform from Market Perform at Raymond James with the firm saying it is uniquely positioned to capitalize on an unexpectedly tight and historically low existing home inventories, while new home demand remains broadly resilient despite rising prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/17/17
NEED
07/17/17
NO CHANGE
Target $94
NEED
Buy
340B exposure a non-issue for Walgreens Boots Alliance, says Needham
Needham analyst Kevin Caliendo notes that CMS proposed a cut to hospital outpatient reimbursement for the purchase of specialty drugs under the 340B program. The analyst believes Walgreens Boots Alliance has the largest exposure to 340B plans. However, the company said that 340B represented less than 1% of total U.S. pharmacy Rxs for the company, Caliendo adds. He reiterates a Buy rating and $94 price target on the shares.
06/30/17
NEED
06/30/17
UPGRADE
NEED
Buy
Walgreens Boots Alliance upgraded to Buy from Hold at Needham
SCSS Select Comfort
$31.81

1.05 (3.41%)

06/29/17
KEYB
06/29/17
NO CHANGE
KEYB
KeyBanc sees only 'modest' synergies from speculated Tempur, Select deal
Shares of both Tempur Sealy (TPX) and Select Comfort (SCSS) are higher after Dealreporter discussed the potential for a transaction, KeyBanc analyst Bradley Thomas tells investors in an intraday research note. Such a deal would have areas for value creation, but seems "more complementary and adjacent," the analyst writes. Further, he does not expect Tempur products to be sold in Select stores. He also calls the timing not ideal for Tempur, saying the company should be focused on keeping sales in the wake of its split with Mattress Firm. Thomas only sees "modest" synergies should the two companies combine. Shares of Select Comfort are up 10% to $35.33 in late afternoon trading while Tempur is up 4% to $53.06.
06/30/17
RAJA
06/30/17
NO CHANGE
RAJA
Tempur Sealy takeover of Select Comfort would not make sense, says Raymond James
After Deal Reporter and Bloomberg reported that Tempur Sealy (TPX) is looking to bid for Select Comfort (SCSS), Raymond James analyst Budd Bugatch says that such a deal would not be logical .The analyst says that it's difficult to sell Select Comfort's Sleep Number bed in a conventional store because of the "longer and more in depth selling process" it requires. As a result, the analyst does not think that it would be logical "to mix products." The analyst adds that there wouldn't be enough room in Sleep Number stores for Tempur-Pedic and Sealy products. Additionally, Bugatch thinks that Tempur Pedic's independent retailer customers would take away floor slots if it made the deal, and the analyst does not think that Tempur Pedic can afford to buy Select Comfort.
07/14/17
PIPR
07/14/17
NO CHANGE
Target $37
PIPR
Overweight
Select Comfort recent weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Peter Keith recommends long-term buyers use the recent weakness in shares of Select Comfort as a buying opportunity. While Q2 numbers are at "slight risk" due to the well-publicized delivery delays, a guidance cut is unlikely, Keith tells investors in a pre-earnings research note. He maintains an Overweight rating on Select Comfort with a $37 price target.
06/29/17
RAJA
06/29/17
NO CHANGE
RAJA
Raymond James downplays hopes of Tempur, Select Comfort deal
Raymond James analyst Budd Bugatch believes the rumored acquisition of Select Comfort (SCSS) by Tempur Sealy (TPX) does not make strategic sense. Such a deal would get a negative reaction from independent retailers and take aware floor slots for both brands, Bugatch told investors in an intraday research note. He tells investors to discount the possibility of such a merger and views the deal as a "stretch" from a financial perspective. Shares of Select Comfort are up 10% to $35.33 in late afternoon trading while Tempur is up 4% to $53.06. Bugatch has a Strong Buy rating on Tempur Sealy and Market Perform rating on Select Comfort.
CBAY CymaBay
$5.98

0.33 (5.84%)

07/17/17
HCWC
07/17/17
NO CHANGE
Target $12
HCWC
Buy
CymaBay price target raised to $12 from $7 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for CymaBay (CBAY) to $12 saying the Phase 2 results of seladelpar in primary biliary cholangitis "are more robust" than Intercept Pharmaceutical's (ICPT) Ocaliva. The analyst notes that his new target reflects increased confidence in the approvability and market potential of seladelpar. He has a Buy rating on CymaBay.
07/17/17
IFSG
07/17/17
NO CHANGE
Target $18
IFSG
Strong Buy
CymaBay price target raised to $18 from $13.50 at IFS Securities
IFS Securities analyst David Bouchey said 12 week top-line results from CymaBay's Phase 2 trial of seladelpar in Primary Biliary Cholangitis provides a strong basis to move on to Phase 3 and he has increased his projections for both seladelpar and arhalofenate. He raised his price target on CymaBay to $18 from $13.50 and keeps a Strong Buy rating on the stock.
07/12/17
OPCO
07/12/17
NO CHANGE
OPCO
CymaBay could see a 76% increment in value, says Oppenheimer
Oppenheimer analyst Jay Olson says CymaBay's shares could see a 76% increment in value if the July interim Phase 2 data for seladelpar supports removal of a partial clinical hold, enabling initiation of longer duration studies. The analyst estimates that the 5 and 10 mg dose in the Phase 2 trial will be efficacious and safe with a 67% probability of success. If positive, the stock price could move to $10 on the news, he adds.
06/22/17
OPCO
06/22/17
INITIATION
Target $8
OPCO
Outperform
CymaBay initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started CymaBay with an Outperform rating and $8 price target.
ETH Ethan Allen
$30.45

-0.15 (-0.49%)

01/26/17
01/26/17
DOWNGRADE

Neutral
Ethan Allen downgraded to Neutral at Dougherty
As previously reported, Dougherty downgraded Ethan Allen to Neutral from Buy following Q2 results. Analyst Jeremy Hamblin changed his views given a lack of visbility on the timing and impact on sales catalysts, including Disney Collection launch and US State Department contract, fewer new product introductions, tough 2H 17 comps, and significant downside risk to consensus FY17 and FY18 estimates.
01/26/17
01/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Market Perform from Outperform at Wells Fargo with analyst Larry Biegelsen saying the company's "disappointing" 2017 revenue guidance suggests its pharma business is facing more headwinds than he expected. J&J guided to underlying sales growth in 2017 of 3.0%-3.5%, which is a "sharp deceleration" from 7.4% underlying growth in 2016, Biegelsen tells investors in a research note. Biegelsen downgraded Johnson & Johnson before the company's announced acquisition of Actelion (ALIOF). He wrote, though, that any deal wouldn't likely close until late 2017. 2. United Technologies (UTX) downgraded to Hold from Buy at Argus with analyst John Eade citing valuation. 3. Ethan Allen (ETH) downgraded to Neutral from Buy at Dougherty with analyst Jeremy Hamblin changing his views given a lack of visibility on the timing and impact on sales catalysts, including Disney Collection launch and US State Department contract, fewer new product introductions, tough second half of 2017 comps, and significant downside risk to consensus fiscal 2017 and fiscal 2018 estimates. 4. Hasbro (HAS) downgraded to Neutral from Buy at Monness Crespi. 5. Mattel (MAT) downgraded to Neutral from Buy at MKM Partners with analyst Eric Handler saying the turnaround story has lost momentum as a slower than expected retail environment, fewer product reorders, and increased promotional activity resulted in disappointing year-end results. Handler expects foreign exchange headwinds, rising input costs, and an unfavorable product mix to continue into 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/17
RAJA
03/14/17
UPGRADE
Target $36
RAJA
Strong Buy
Ethan Allen upgraded to Strong Buy from Market Perform at Raymond James
Raymond James analyst Budd Bugatch double upgraded Ethan Allen to Strong Buy from Market Perform saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. The analyst has a $36 price target for the shares.
03/14/17
03/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Buy from Neutral at Guggenheim with analyst Michael Morris upgraded saying that he still sees strong potential upside despite the stock's move off its lows as the company enters another expansion cycle for its film, consumer products and parks businesses. The analyst is more cautious on the Networks business, both for Disney and the broader industry, but thinks that is reflected already in Disney shares. Morris raised his price target on Disney shares to $128 from $118. 2. Dick's Sporting (DKS) upgraded to Outperform from Peer Perform at Wolfe Research. 3. Quest Diagnostics (DGX) upgraded to Conviction Buy from Buy at Goldman with analyst Isaac Ro saying the company should be a key beneficiary as the U.S. healthcare system shifts the cost burden to the individual and creates price transparency for the first time. 4. Olympic Steel (ZEUS) and Reliance Steel (RS) were upgraded to Outperform from Neutral at Macquarie, while Worthington (WOR) was upgraded to Neutral from Underperform. 5. Ethan Allen (ETH) upgraded to Strong Buy from Market Perform at Raymond James with analyst Budd Bugatch double upgrading the company saying sales comparisons get easier through 2017 while the retailer's remerchandising effort is behind it, thereby lowering the clearance markdowns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VNOM Viper Energy
$16.20

0.03 (0.19%)

02/21/17
RAJA
02/21/17
UPGRADE
Target $23
RAJA
Strong Buy
Viper Energy upgraded to Strong Buy from Market Perform at Raymond James
Raymond James anlasyt John Freeman upgraded Viper Energy to Strong Buy from Market Perform and established a $23 price target saying the market should be too preoccupied with "weak" 2017 guidance. Freeman has increased confidence Viper can outperform significantly following additional clarity into the company's drilling inventory resulting in a doubling of tier-1 Spanish Trail locations, increased visibility into accretive dropdowns/acquisitions, and views Viper as a potential candidate to be added to the Alerian MLP index later this year.
03/31/17
SBSH
03/31/17
INITIATION
Target $20
SBSH
Buy
Viper Energy initiated with a Buy at Citi
Citi analyst Faisel Khan started Viper Energy Partners LP with a Buy rating and $20 price target. The partnership gives investors an opportunity to receive a growing income stream from one of the "most prolific producing basins" in the U.S., the Permian, the analyst contends.
05/26/17
PIPR
05/26/17
INITIATION
Target $22
PIPR
Overweight
Viper Energy assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst David Kistler assumed coverage of Viper Energy with an Overweight rating and $22 price target.
02/21/17
02/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Buy from Neutral at MoffettNathanson by analyst Craig Moffett, who said its 2017 earnings trajectory is better than AT&T's (T) and most, if not all, of the bad news is reflected in valuation. 2. Community Health (CYH) upgraded to Neutral from Underperform at Mizuho by analyst Dr. Sheryl Skolnick, who believes Community Health may have given itself some breathing room ahead of its looming 2018/19 maturity wall and taken some credit induced pressure off the stock with its inline Q4 EBITDA report and reasonable 2017 guidance. 3. Meritor (MTOR) upgraded to Overweight from Sector Weight at KeyBanc by analyst Brett Hoselton, who said higher North America Class 8 production and net new business will likely drive revenue growth ahead of consensus expectations. 4. Viper Energy (VNOM) upgraded to Strong Buy from Market Perform at Raymond James by analyst John Freeman, who has increased confidence Viper can outperform significantly following additional clarity into the company's drilling inventory and views Viper as a potential candidate to be added to the Alerian MLP index later this year. 5. Laredo Petroleum (LPI) upgraded to Overweight from Neutral at Piper Jaffrayby analyst Kashy Harrison, citing valuation and the company's improved balance sheet. The analyst sees upside to 2018 consensus production estimates. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, URL
NLY Annaly Capital
$12.26

-0.07 (-0.57%)

12/20/16
FBRC
12/20/16
DOWNGRADE
Target $10
FBRC
Market Perform
Annaly Capital downgraded to Market Perform from Outperform at FBR Capital
FBR Capital analyst Jessica Levi-Ribner downgraded Annaly Capital to Market Perform saying a discount to book is appropriate given her expectation for fixed-income market volatility and rising rates in FY17. The analyst lowered her price target for the shares to $10 from $12.
12/15/16
BOFA
12/15/16
DOWNGRADE
Target $9
BOFA
Neutral
Annaly Capital downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Kenneth Bruce downgraded Annaly Capital to Underperform and lowered its price target to $9 from $11. The analyst sees risk to mortgage related stocks in a rising rate environment with increased volatility as rate sensitive assets erode book value and a flatter yield cure pressures earnings. The firm believes deflation has peaked, and the expected unwind will result in sector rotation out of bonds.
F Ford
$11.74

0.06 (0.51%)

06/21/17
GUGG
06/21/17
INITIATION
Target $13
GUGG
Neutral
Ford initiated with a Neutral at Guggenheim
Guggenheim analyst Emmanuel Rosner started Ford with a Neutral rating and $13 price target.
06/13/17
WOLF
06/13/17
INITIATION
Target $10
WOLF
Peer Perform
Ford initiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Chris Bottiglieri initiated Ford with a Peer Perform and a $10 price target citing risks from high gross leverage, increasing spending requirements, conservative positioning, and increasing competition.
06/08/17
MSCO
06/08/17
NO CHANGE
MSCO
Morgan Stanley makes "big" cuts to US Auto Sales forecasts
Morgan Stanley analyst Adam Jonas made "big" cuts to his US auto industry sales forecast, reducing his 2017 US SAAR forecast to 17.3M units from 18.3M units, 2018 to 16.4M units from 18.9M units, 2019 to 15M units from 19.2M units, and 2020 to 15M units from 18.7M units. Jonas believes the auto cycle may be hitting a point of diminishing returns following 8 years into the biggest cycle on record as used car values erode, pressuring conditions for selling new vehicles, and said new vehicle inventory levels continue to rise. Additionally, the analyst expects electrical margins to face increasing competition from new entrants and higher development costs. As a result, Jonas cut estimates across the board and downgraded Lear (LEA) to Underweight from Equal Weight.
06/07/17
MSCO
06/07/17
NO CHANGE
Target $10
MSCO
Underweight
Ford earnings outlook may need to be cut as much as 50%, says Morgan Stanley
Morgan Stanley analyst Adam Jonas said in a note published prior to the open that its "not at all unprecedented" for a new leadership team to reassess long-term priorities at the cost of near-term results and he believes Ford's earnings outlook may need to be reset by as much as 50% lower following the appointment of Jim Hackett as CEO. With the right strategic repositioning, Ford may be able to transform into a "mega-fleet manager and gatekeeper to billions of vehicle miles traveled" over many years, but near-term consensus expectations are vulnerable as it begins that journey, said Jonas, who keeps an Underweight rating and $10 price target on Ford shares.

TODAY'S FREE FLY STORIES

10:30
10/19/17
10/19
10:30
10/19/17
10:30
General news
EIA natural gas storage change for week ending October 13 »

Gas inventories 51 Bcf…

MU

Micron

$41.65

1.26 (3.12%)

10:30
10/19/17
10/19
10:30
10/19/17
10:30
Options
Active trading in Micron calls as shares slump Thursday »

Active trading in Micron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

NKE

Nike

$52.21

-0.0915 (-0.17%)

, ADDYY

adidas

$112.54

-0.08 (-0.07%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Hot Stocks
Goldman Sachs cuts Nike rating ahead of investor day on excess inventory »

This morning, Goldman…

NKE

Nike

$52.21

-0.0915 (-0.17%)

ADDYY

adidas

$112.54

-0.08 (-0.07%)

GRPN

Groupon

$5.00

0.05 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 01

    Nov

  • 16

    Nov

ULTA

Ulta Beauty

$200.90

2.59 (1.31%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Rumors
Rumor moving shares of Ulta Beauty »

Rumor: Ulta Beauty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/19/17
10/19
10:25
10/19/17
10:25
General news
Today's U.S. reports »

Today's U.S. reports…

UAL

United Continental

$64.26

-3.73 (-5.49%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Technical Analysis
Technical View: United Continental falls after results and outlook »

The company reported Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MEIP

MEI Pharma

$2.48

0.15 (6.44%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Hot Stocks
MEI Pharma's pracinostat granted EU orphan designation »

Pracinostat was granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$50.08

1.431 (2.94%)

10:20
10/19/17
10/19
10:20
10/19/17
10:20
Options
Notable ratio spread in Verizon as shares rally on earnings »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

10:20
10/19/17
10/19
10:20
10/19/17
10:20
General news
Treasury Action: yields resumed their slide »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

10:17
10/19/17
10/19
10:17
10/19/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
10/19/17
10/19
10:16
10/19/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.76

0.25 (0.39%)

, TEVA

Teva

$14.61

-0.01 (-0.07%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Periodicals
Merck wins appeal to revive NuvaRing patent case against Teva, Bloomberg says »

An appeals court said a…

MRK

Merck

$63.76

0.25 (0.39%)

TEVA

Teva

$14.61

-0.01 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 27

    Oct

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 02

    Feb

ADP

ADP

$113.93

0.21 (0.18%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Hot Stocks
Pershing Square releases additional questions for ADP »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
U.S. leading economic index fell 0.2% to 128.6 in September »

U.S. leading economic…

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
Breaking General news story  »

Week of 10/13 EIA Natural…

GS

Goldman Sachs

$240.07

-1.96 (-0.81%)

10:13
10/19/17
10/19
10:13
10/19/17
10:13
Hot Stocks
Blankfein: 'Just left Frankfurt,' 'I'll be spending a lot more time there' »

Goldman Sachs Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

EVHC

Envision Healthcare

$40.70

0.05 (0.12%)

10:11
10/19/17
10/19
10:11
10/19/17
10:11
Periodicals
Starboard's Smith to pitch Envision Healthcare as long idea, Bloomberg says »

Starboard Value's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NNI

Nelnet

$51.05

-0.27 (-0.53%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Upgrade
Nelnet rating change  »

Follow-up: Nelnet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.30

0.4 (3.36%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Options
Short-term call buyer in Ceaser's opens a notable new position »

Short-term call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

MMP

Magellan Midstream

$67.56

-0.96 (-1.40%)

10:09
10/19/17
10/19
10:09
10/19/17
10:09
Hot Stocks
Magellan Midstream raises quarterly distribution to 90.5c per unit »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

MDB

MongoDB

10:07
10/19/17
10/19
10:07
10/19/17
10:07
Syndicate
MongoDB indicated to open at $33, IPO priced at $24 »

MongoDB (MDB) priced 8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

HMNY

Helios and Matheson

$16.32

-1.91 (-10.48%)

10:05
10/19/17
10/19
10:05
10/19/17
10:05
Rumors
Rumor moving shares of Helios and Matheson »

Rumor: Helios and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNI

Nelnet

$51.05

-0.27 (-0.53%)

10:02
10/19/17
10/19
10:02
10/19/17
10:02
Upgrade
Nelnet rating change  »

Nelnet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:02
10/19/17
10/19
10:02
10/19/17
10:02
General news
Leading Indicators data reported »

September Leading…

FB

Facebook

$176.03

-0.08 (-0.05%)

10:02
10/19/17
10/19
10:02
10/19/17
10:02
Technical Analysis
Technical View: Facebook hits session lows, levels to watch »

Shares have come off life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.